Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

This study has been terminated.
(Five immune related serious adverse events)
Cancer Prevention Research Institute of Texas
Information provided by (Responsible Party):
Mirna Therapeutics, Inc. Identifier:
First received: April 8, 2013
Last updated: September 26, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: May 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)